Zoetis Inc (ZTS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $34.06B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zoetis Inc (ZTS) Earnings: Report Dates and Results
Zoetis (ZTS) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Zoetis reported EPS of $1.75, above the $1.51 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ZTS has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 18.9% below the $1.48 reported for the quarter ended Dec 31, 2025.
ZTS Earnings Call
The latest ZTS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ZTS beat 33, missed 4 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $2.39B, down 1.2% from $2.42B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.75 | $1.51 | $1.44 - $1.61 | +15.89% | Beat | +2.9% | 13 | 0 up, 13 down | Nov 5, 2026 | $2.39B |
| Jun 30, 2026 | $1.87 | $1.84 | $1.77 - $1.90 | +1.63% | Beat | +6.3% | 14 | 0 up, 1 down | Aug 6, 2026 | $2.47B |
| Mar 31, 2026 | $1.53 | $1.62 | $1.56 - $1.65 | -5.56% | Miss | +3.4% | 15 | 0 up, 6 down | May 7, 2026 | $2.26B |
| Dec 31, 2025 | $1.48 | $1.40 | $1.38 - $1.43 | +5.71% | Beat | +5.7% | 16 | 2 up, 0 down | Feb 12, 2026 | $2.39B |
| Sep 30, 2025 | $1.70 | $1.62 | $1.59 - $1.65 | +4.94% | Beat | +7.6% | 12 | 1 up, 5 down | Nov 4, 2025 | $2.42B |
| Jun 30, 2025 | $1.76 | $1.61 | $1.57 - $1.66 | +9.32% | Beat | +12.8% | 12 | 4 up, 0 down | Aug 5, 2025 | $2.47B |
| Mar 31, 2025 | $1.48 | $1.40 | $1.34 - $1.47 | +5.71% | Beat | +7.2% | 13 | 0 up, 4 down | May 6, 2025 | $2.20B |
| Dec 31, 2024 | $1.40 | $1.36 | $1.05 - $1.42 | +2.94% | Beat | +12.9% | 13 | 1 up, 4 down | Feb 13, 2025 | $2.32B |
| Sep 30, 2024 | $1.58 | $1.46 | $1.42 - $1.50 | +8.22% | Beat | +16.2% | 11 | 0 up, 0 down | Nov 4, 2024 | $2.39B |
| Jun 30, 2024 | $1.56 | $1.48 | $1.46 - $1.53 | +5.41% | Beat | +10.6% | 11 | 0 up, 0 down | Aug 6, 2024 | $2.36B |
| Mar 31, 2024 | $1.38 | $1.34 | $1.26 - $1.38 | +2.99% | Beat | +5.3% | 10 | 0 up, 2 down | May 2, 2024 | $2.19B |
| Dec 31, 2023 | $1.24 | $1.32 | $1.21 - $1.35 | -6.06% | Miss | +7.8% | 10 | 2 up, 0 down | Feb 13, 2024 | $2.21B |
| Sep 30, 2023 | $1.36 | $1.36 | $1.33 - $1.41 | 0.00% | In line | +12.4% | 9 | 0 up, 1 down | Nov 2, 2023 | $2.15B |
| Jun 30, 2023 | $1.41 | $1.31 | $1.26 - $1.36 | +7.63% | Beat | +17.5% | 11 | 2 up, 0 down | Aug 8, 2023 | $2.18B |
| Mar 31, 2023 | $1.31 | $1.25 | $1.18 - $1.31 | +4.80% | Beat | -0.8% | 10 | 0 up, 0 down | May 4, 2023 | $2.00B |
| Dec 31, 2022 | $1.15 | $1.15 | $0.01 - $1.18 | 0.00% | In line | +15.0% | 11 | 3 up, 0 down | Feb 14, 2023 | $2.04B |
| Sep 30, 2022 | $1.21 | $1.24 | $1.16 - $1.31 | -2.42% | Miss | -3.2% | 12 | 0 up, 3 down | Nov 3, 2022 | $2.00B |
| Jun 30, 2022 | $1.20 | $1.22 | N/A | -1.64% | Miss | +0.8% | N/A | 1 up, 1 down | Aug 4, 2022 | $2.05B |
| Mar 31, 2022 | $1.32 | $1.22 | $1.11 - $1.30 | +8.20% | Beat | +4.8% | 11 | 1 up, 1 down | May 5, 2022 | $1.99B |
| Dec 31, 2021 | $1.00 | $0.96 | $0.91 - $1.00 | +4.17% | Beat | +9.9% | 13 | 0 up, 0 down | Feb 15, 2022 | $1.97B |
| Sep 30, 2021 | $1.25 | $1.11 | $1.00 - $1.19 | +12.61% | Beat | +13.6% | 13 | N/A | Nov 4, 2021 | $1.99B |
| Jun 30, 2021 | $1.19 | $1.09 | $1.02 - $1.17 | +9.17% | Beat | +33.7% | 15 | N/A | Aug 5, 2021 | $1.95B |
| Mar 31, 2021 | $1.26 | $1.04 | $0.96 - $1.10 | +21.15% | Beat | +32.6% | 15 | N/A | May 6, 2021 | $1.87B |
| Dec 31, 2020 | $0.91 | $0.87 | $0.84 - $0.90 | +4.60% | Beat | -1.1% | 16 | N/A | Feb 16, 2021 | $1.81B |
| Sep 30, 2020 | $1.10 | $0.92 | $0.83 - $1.00 | +19.57% | Beat | +17.0% | 17 | N/A | Nov 5, 2020 | $1.79B |
| Jun 30, 2020 | $0.89 | $0.65 | $0.44 - $0.74 | +36.92% | Beat | -1.1% | 16 | N/A | Aug 6, 2020 | $1.55B |
| Mar 31, 2020 | $0.95 | $0.87 | $0.73 - $0.94 | +9.20% | Beat | +8.0% | 15 | N/A | May 6, 2020 | $1.53B |
| Dec 31, 2019 | $0.92 | $0.88 | $0.84 - $0.89 | +4.55% | Beat | +16.5% | 14 | N/A | Feb 13, 2020 | $1.67B |
| Sep 30, 2019 | $0.94 | $0.89 | $0.78 - $0.92 | +5.62% | Beat | +13.3% | 14 | N/A | Nov 7, 2019 | $1.58B |
| Jun 30, 2019 | $0.90 | $0.82 | $0.73 - $0.86 | +9.76% | Beat | +16.9% | 14 | N/A | Aug 6, 2019 | $1.55B |
| Mar 31, 2019 | $0.88 | $0.79 | $0.75 - $0.84 | +11.39% | Beat | +17.3% | 13 | N/A | May 2, 2019 | $1.46B |
| Dec 31, 2018 | $0.79 | $0.77 | $0.73 - $0.81 | +2.60% | Beat | +14.5% | 12 | N/A | Feb 14, 2019 | $1.56B |
| Sep 30, 2018 | $0.83 | $0.77 | $0.73 - $0.85 | +7.79% | Beat | +27.7% | 13 | N/A | Nov 1, 2018 | $1.48B |
| Jun 30, 2018 | $0.77 | $0.70 | $0.65 - $0.74 | +10.00% | Beat | +45.3% | 15 | N/A | Aug 2, 2018 | $1.42B |
| Mar 31, 2018 | $0.75 | $0.69 | $0.65 - $0.74 | +8.70% | Beat | +41.5% | 17 | N/A | May 2, 2018 | $1.37B |
| Dec 31, 2017 | $0.69 | $0.66 | $0.63 - $0.69 | +4.55% | Beat | +46.8% | 17 | N/A | Feb 15, 2018 | $1.46B |
| Sep 30, 2017 | $0.65 | $0.62 | $0.57 - $0.66 | +4.84% | Beat | +25.0% | 17 | N/A | Nov 2, 2017 | $1.35B |
| Jun 30, 2017 | $0.53 | $0.53 | $0.49 - $0.59 | 0.00% | In line | +8.2% | 17 | N/A | Aug 8, 2017 | $1.27B |
| Mar 31, 2017 | $0.53 | $0.48 | N/A | +10.42% | Beat | +10.4% | N/A | N/A | May 4, 2017 | $1.23B |
| Dec 31, 2016 | $0.47 | $0.45 | N/A | +4.44% | Beat | +9.3% | N/A | N/A | Feb 16, 2017 | $1.28B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.42, up 8.4% from the year before. It was $1.96 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.42 | +8.4% |
| Dec 31, 2024 | $5.92 | +11.3% |
| Dec 31, 2023 | $5.32 | +9.0% |
| Dec 31, 2022 | $4.88 | +3.8% |
| Dec 31, 2021 | $4.70 | +22.1% |
| Dec 31, 2020 | $3.85 | +5.8% |
| Dec 31, 2019 | $3.64 | +15.9% |
| Dec 31, 2018 | $3.14 | +30.8% |
| Dec 31, 2017 | $2.40 | +22.4% |
| Dec 31, 2016 | $1.96 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,832 | 14 | |
| 2026Q2 | Jun 30, 2026 | 8,853 | 11 | |
| 2026Q1 | Mar 31, 2026 | 9,241 | 14 | |
| 2025Q4 | Dec 31, 2025 | 9,818 | 15 | |
| 2025Q3 | Sep 30, 2025 | 6,780 | 9 | |
| 2025Q2 | Jun 30, 2025 | 8,046 | 14 | |
| 2025Q1 | Mar 31, 2025 | 8,712 | 13 | |
| 2024Q4 | Dec 31, 2024 | 8,979 | 14 |
2026Q3 Earnings Call
Opening remarks
Mathieu Aussermeier Senior Vice President, Corporate Finance Thank you, operator. Good morning, everyone, and welcome to the Zoetis third quarter 2026 earnings call. I am joined today by Kristin Peck, Chief Executive Officer, and Jay Saccaro, Chief Financial Officer and Chief Operating Officer. This morning, we issued a press release announcing our third quarter 2026 financial results. Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website, and that many of our statements today may be considered forward-looking statements and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our company's Exchange Act reports filed with the SEC. Additionally, today's remarks will include certain non-GAAP financial measures. Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures can be found in our earnings press release and our company's 8-K filing dated today, November 5th, 2026. We will also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impact Zoetis' growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance. With that, I will turn the call over to Kristin. Kristin?
Kristin Peck CEO Thank you, Mathieu. Good morning, everyone, and thank you for joining us. Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations. Our diversified portfolio provided some resilience, and we focused on defending leadership positions with investments in key franchises. At the same time, we continued advancing the portfolio and innovation pipeline. While challenging dynamics are continuing, we are seeing progress in the actions we are taking and have narrowed our full-year revenue guidance to the high end of our range. As I walk you through our performance, I want to put the industry and company results in perspective and outline how we are positioning Zoetis for the near and long term. But first, I am pleased to welcome Jay to his first earnings call with Zoetis. He brings a strong track record and a valuable combination of financial and operating experience, and we're excited to have him on the team. With that, let me start with what we see across the industry. As you all know, animal health remains a long-term secular growth industry, driven by a growing global population looking to eat more protein and adopt and care for more pets.
Frequently Asked Questions About ZTS
When is Zoetis's next earnings date?
Zoetis's next earnings report is expected for Feb 10, 2027.
Did ZTS beat earnings estimates last quarter?
Yes. Zoetis reported EPS of $1.75 for the quarter ended Sep 30, 2026, above the $1.51 estimate, a 15.89% surprise.
What EPS do analysts expect from ZTS next quarter?
The consensus EPS estimate for Zoetis for the quarter ending Dec 31, 2026 is $1.20 from 15 analysts, with estimates from $1.12 to $1.35.
How often does ZTS beat earnings estimates?
Zoetis beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +5.07%.
ZTS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts